Olatec Therapeutics LLC (“Olatec”) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimer’s Disease (AD). The data are published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS). The study shows...
Read Full StoryIf the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com
Top News
Related
DISEASE PREVENTION AND TREATMENT
Watch now: Some Bloomington-Normal dentist adds new role: vaccine clinic volunteer
, 5min
0
DISEASE PREVENTION AND TREATMENT
, 18min
0
, 31min
0
DISEASE PREVENTION AND TREATMENT
Scientific safety workgroup recommends Johnson & Johnson vaccine
, 31min
0
DISEASE PREVENTION AND TREATMENT
All your questions about the Oxford-AstraZeneca vaccine answered
, 31min
0
DISEASE PREVENTION AND TREATMENT
3 Things You Should Do To Avoid A Headache, According To Neuroscientists
, 34min
0
DISEASE PREVENTION AND TREATMENT
Not a single vaccine has gone to waste at the Civic Center, according to Lubbock Health Department
, 41min
0
Comments